Carrum Health announced a partnership with Accolade (Nasdaq: ACCD) to deliver a fully integrated healthcare experience with proven cost savings and improved care outcomes. Accolade clients can now easily activate Carrum’s value-based COE program through their existing contract and quickly offer their employees access to personalized guidance and treatment from best-in-class providers that have been rigorously evaluated and selected using industry-leading quality algorithms.
“When faced with a major medical event like surgery, cancer, or childbirth, patients are often overwhelmed by the healthcare system, and worst of all the financial stress and uncertainty of medical bills. Carrum Health gives patients peace of mind by assuring the most appropriate and highest quality care for zero or minimal out of pocket costs,” said Brent Nicholson, co-founder and chief partner officer for Carrum Health. “Our partnership with Accolade further substantiates that there is a better way to pay for and deliver healthcare, especially now as employers look to reduce healthcare costs while delivering improved outcomes and experiences for their employees.”
Carrum Health is the only COE provider to offer a patient-facing app to guide members through their entire COE experience and also launched the industry’s first bundled cancer care for employers, in partnership with the nation’s leading cancer institutions like Memorial Sloan Kettering and City of Hope. The platform supports members in need of musculoskeletal, bariatric, oncology, cardiac and maternity care through a value-based bundled payment solution.
Monod Bio, a life sciences company developing custom diagnostic biosensors, has raised a $25 million seed round. Matrix Capital led the round, with participation from the Global Health Investment Corp., Cercano Management, The Washington Research Foundation, Boom Capital Ventures, Sahsen Ventures, and Pack Ventures.
“We can now design custom biosensors that have specific functions, and this seed financing enables us to illuminate specific molecules such as viruses or biomarkers, and start building prototypes that can then become real-world diagnostics,” said Daniel-Adriano Silva, Monod Bio CEO and co-founder, in the press release.
“We know these new biosensors can readily detect virus proteins or antibodies in simulated nasal fluid or donated serum. Our next goal is to ensure they can be used reliably in a diagnostic setting. Monod Bio’s work illustrates the power of de novo protein design to create molecular devices from scratch with new and useful functions,” said David Baker, Ph.D., the Henrietta and Aubrey Davis Endowed professor of biochemistry at the University of Washington School of Medicine and Monod Bio co-founder, according to the release.
To read more, click here.
This week, Sema4 cut 250 staff, about 13% of its workforce, as part of a series of cost-cutting measures initiated in the first half of the year. Founder Eric Schadt has resigned from his roles as president and chief research and development officer, as well as his position as a director of the company. Since the beginning of 2022, Sema4 has eliminated 30% of roles from the business.
To read more, click here.
Evry Health, a health tech company focused on employer health insurance, has expanded to Austin, Houston and San Antonio from its Dallas-Fort Worth base. The startup, which launched earlier this year, has developed software automation tools seeking to lower healthcare costs for businesses.
“Expanding our services outside of DFW will help thousands more people have access to great benefits without having to pay exorbitant prices,” said Chris Gay, Evry Health CEO, in a press release. “Our team has worked hard to provide an innovative group health insurance plan that is within reach for Austin, San Antonio and Houston residents.”
To read more, click here.
Trulla, one of the healthcare industry’s leading providers of pharmacy procurement software, has been acquired by SpendMend, a company that develops solutions to optimize the cost cycle for healthcare.
Curtis McEntire, the CEO of Trulla, founded the business in 2018. McEntire is a former executive in pharmacy sourcing and supply chain at Intermountain Healthcare.
The acquisition of Trulla by SpendMend is made in partnership with Morgan Stanley Capital Partners as part of a strategic initiative to expand the value of the SpendMend Pharmacy division, according to the press release.
To read more, click here.
Picture: akindo, Getty Images
